Skip to main content

Day: April 6, 2020

Savencia SA : communiqué de mise à disposition des documents d’Assembvlée Générale

SAVENCIA SA informe ses actionnaires qu’ils sont convoqués en Assemblée Générale Mixte (Ordinaire et Extraordinaire) le :Jeudi 23 avril 2020 à 10 heures 30au siège social : 42 rue Rieussec – 78220 VIROFLAY (*)L’avis de réunion a été publié au Bulletin des Annonces Légales et Obligatoires (BALO) du 16 mars 2020.L’avis de réunion qui contient notamment l’ordre du jour de cette assemblée et les projets de résolutions qui lui seront soumis ainsi que leur présentation, peuvent être consultés dans l’espace Assemblée Générale du site Internet de la société (http://www.savencia-fromagedairy.com)Les documents et renseignements relatifs à cette assemblée sont tenus à la disposition des actionnaires dans les conditions légales et réglementaires.Viroflay le 2 avril 2020Pièce jointecommunique de mise a disposition doc AG

Continue reading

Aktietilbagekøb i Danske Andelskassers Bank A/S – transaktioner i uge 14

Selskabsmeddelelse nr. 19/2020 | 6. april 2020Den 1. oktober 2019 iværksatte Danske Andelskassers Bank A/S’ (”Banken”) et aktietilbagekøbsprogram. Aktietilbagekøbsprogrammet løber i perioden fra 1. oktober 2019 til 30. september 2020. I denne periode vil Banken opkøbe aktier for en maksimal værdi af 16.898.800 kroner, jf. selskabsmeddelelse nr. 18 af 24. september 2019.Under aktietilbagekøbsprogrammet er følgende transaktioner gennemført:Efter ovenstående transaktioner ejer Banken i alt 1.701.717 egne aktier svarende til 0,9756% af Bankens aktiekapital.Siden aktietilbagekøbsprogrammet blev iværksat den 1. oktober 2019, er der samlet købt 1.483.000 aktier for et samlet beløb på 10.559.199 kroner.Alle transaktioner er foretaget i ISIN DK0060299063.Vedhæftet fil19- 2020 Selskabsmeddelelse_Aktietilbagekøb uge 14

Continue reading

Continuous Renal Replacement Therapy Market to Exhibit 7.5% CAGR; High Incidence of Hypertension to Propel Growth, says Fortune Business Insights™

Pune, April 06, 2020 (GLOBE NEWSWIRE) — The global continuous renal replacement therapy (CRRT) market is set to be positively impacted by rising technological advancements by renowned acute therapy manufacturers to offer enhanced dialysis care worldwide. Also, the expansion of extracorporeal therapies taking place in the ICU would affect the market positively. This information is given by Fortune Business Insights™ in a recent report, titled, “Continuous Renal Replacement Therapy (CRRT) Market Size, Share & Industry Analysis, By Product (Systems, and Consumables), By Modality (Slow continuous ultra-filtration {SCUF}, Continuous Venovenous Hemofiltration {CVVH}, Continuous Venovenous Haemodialysis {CVVHD}, and Continuous Venovenous Hemodiafiltration {CVVHDF), and Regional Forecast, 2019-2026.” The report further mentions that...

Continue reading

Scatec Solar’s 258 MW Upington project in South Africa completed

Oslo, 6 April 2020: Scatec Solar and partners have grid connected and started commercial operation of the third 86 MW solar plant in Upington, South Africa, completing the 258 MW solar power complex. The 86 MW facility, known as Dyason’s Klip 2, is expected to produce 217 GWh annually.“We are proud to have achieved this major milestone. Power supply is considered critical infrastructure, and we are pleased to be supporting South African power supply with renewable energy to another 40,000 households annually, says Raymond Carlsen, CEO of Scatec Solar.The Upington solar power complex is estimated to deliver an annual production of 650 GWh, providing clean energy to around 120,000 households and lead to the abatement of more than 600,000 tonnes of CO² emissions annually.The three projects in Upington were awarded in April 2015 in the fourth...

Continue reading

SEK CREDIT OPERATION ANNOUNCEMENT 2020-04-06

SEK CREDIT OPERATION ANNOUNCEMENT 2020-04-06All approved counterparties are invited to submit volume bids to the Riksbank,tel + 46 8 6966970 by 11.30 am on April 6, 2020.Confirmation of bids to e-mail: eol@riksbank.seResult of the auction will be published at 11.45 (CEST)Complete terms and conditions can be retrieved at http://www.riksbank.se 

Continue reading

Crcam Sud Rhone Alpes : Avis de modification des résolutions d’affectation du résultat

CAISSE REGIONALE DE CREDIT AGRICOLE MUTUEL SUD RHONE ALPES SOCIETE COOPERATIVE A CAPITAL VARIABLEAu capital actuel de 69 850 962,75 euros Siège social :12 Place de la Résistance – CS 20067 –38041 GRENOBLE CEDEX 9 402 121 958 RCS GRENOBLEAvis de modification des résolutions d’affectation du résultat soumises à l’assemblée générale du 14/04/2020 suite à la recommandation BCE du 27 mars 2020Dans sa recommandation du 27 mars 2020, la Banque Centrale Européenne (BCE) a demandé à toutes les banques à compter du 1er avril 2020 :de s’abstenir de distribuer des dividendes au moins jusqu’au 1er octobre 2020 pendant la période de choc économique liée au COVID-19 pour conserver autant de fonds propres que possible et maintenir leur capacité à soutenir l’économie dans un contexte d’incertitude accrue causé par le COVID-19de ne souscrire...

Continue reading

Coloplast A/S – Transactions in connection with share buy-back programme, week 14

As mentioned in Announcement no. 02/2020 Coloplast is initiating a share buyback programme totalling up to DKK 500 million.The programme will commence on 24 February 2020 and is expected to end by 24 August 2020.The share buyback programme is carried out in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052, also referred to as the Safe Harbour Regulations with the purpose of meeting obligations arising from share options programmes or other allocation of shares to employees or to complete a share capital decrease as set out in Articles 5(2)(a) and 5(2)(c) in MAR.The following transactions have been executed during the period 30 March – 3 April 2020:Henceforth, Coloplast owns 3,296,386 treasury B shares of DKK 1 equal...

Continue reading

Coloplast A/S – Transaktioner i henhold til aktietilbagekøbsprogram, uge 14

Som meddelt i Selskabsmeddelelse nr. 02/2020 har Coloplast iværksat et tilbagekøbsprogram på i alt 500 millioner kroner. Programmet begyndte den 24. februar 2020 og forventes afsluttet den 24. august 2020.Aktietilbagekøbsprogrammet struktureres i henhold til bestemmelserne i artikel 5 i EU-Parlamentet og Rådets forordning nr. 596/2014 af 16. april 2014 (MAR) og forordning 2016/1052, også kaldet ”Safe Harbour” reglerne, med det formål at opfylde forpligtelser i henhold til aktieoptionsprogrammer eller andre aktieallokeringer til medarbejdere eller at gennemføre en kapitalnedsættelse i henhold til artikel 5(2)(a) og artikel 5(2)(c) i MAR.                         I perioden 30. marts – 03. april 2020 er der foretaget følgende køb:Coloplast ejer herefter 3.296.386 egne B-aktier à DKK 1 svarende til 1,53 % af selskabets samlede aktiekapital.Separat...

Continue reading

Status på aktietilbagekøbsprogram

Aktietilbagekøbsprogram:Som annonceret i selskabsmeddelelse 10/2020, og præciseret i selskabsmeddelelse 12/2020, har SIG påbegyndt et aktietilbagekøbsprogram som løber i perioden fra og med den 1. april 2020 til og med den 1. oktober 2020.I denne periode vil Selskabet købe egne aktier op til maksimalt 10,0% af aktiekapitalen i et aktietilbagekøbsprogram efter bestemmelserne i EU’s forordning nr. 596/2014 af 16. april 2014 og EU’s forordning nr. 2016/1052 om supplerende regler til forordning nr. 596/2014, den såkaldte ”Safe Harbour” metode, som værner børsnoterede selskaber og deres bestyrelse og direktion imod overtrædelse af forbuddene mod markedsmisbrug i forbindelse med aktie­tilbagekøb.En oversigt over foretagne transaktioner fremgår af vedhæftede. Kontakt:Evt. spørgsmål til denne meddelelse kan rettes til CEO Michael Hove på 28126609...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.